TCDA Tricida Inc.

33.4
-0.69  -2%
Previous Close 34.09
Open 34.21
Price To Book 5.32
Market Cap 1,663,320,000
Shares 49,800,000
Volume 287,360
Short Ratio
Av. Daily Volume 357,483
Stock charts supplied by TradingView

NewsSee all news

  1. Tricida to Present at the 38th Annual J. P. Morgan Healthcare Conference

    Tricida, Inc. (NASDAQ:TCDA) today announced that it will present at the 38th Annual J. P. Morgan Healthcare Conference on Tuesday, January 14, 2020 at 9:30 am PT / 12:30 pm ET. Gerrit Klaerner, Ph.D., Tricida's Founder,

  2. Tricida Announces Hiring of Elizabeth Faust, Ph.D., as Senior Vice President of Medical Affairs

    Tricida, Inc. (NASDAQ:TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic

  3. Tricida to Present at the Evercore Annual Global Healthcare Conference

    Tricida, Inc. (NASDAQ:TCDA) today announced that it will present at the Evercore ISI 2nd Annual Health Care Conference on Tuesday, December 3, 2019 at 5:00 am PT / 8 am ET. Gerrit Klaerner, Ph.D., Tricida's Founder,

  4. Tricida Announces Third Quarter 2019 Financial Results

    FDA Accepts New Drug Application for Veverimer Webcast Today at 4:30 pm Eastern Time Tricida, Inc. (NASDAQ:TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate,

  5. Tricida Announces FDA Acceptance of New Drug Application for Veverimer

    Tricida, Inc. (NASDAQ:TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

PDUFA date August 22, 2020. Advisory Committee Meeting expected.
TRC 101
Chronic kidney disease

Latest News

  1. Tricida to Present at the 38th Annual J. P. Morgan Healthcare Conference

    Tricida, Inc. (NASDAQ:TCDA) today announced that it will present at the 38th Annual J. P. Morgan Healthcare Conference on Tuesday, January 14, 2020 at 9:30 am PT / 12:30 pm ET. Gerrit Klaerner, Ph.D., Tricida's Founder,

  2. Tricida Announces Hiring of Elizabeth Faust, Ph.D., as Senior Vice President of Medical Affairs

    Tricida, Inc. (NASDAQ:TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic

  3. Tricida to Present at the Evercore Annual Global Healthcare Conference

    Tricida, Inc. (NASDAQ:TCDA) today announced that it will present at the Evercore ISI 2nd Annual Health Care Conference on Tuesday, December 3, 2019 at 5:00 am PT / 8 am ET. Gerrit Klaerner, Ph.D., Tricida's Founder,

  4. Tricida Announces Third Quarter 2019 Financial Results

    FDA Accepts New Drug Application for Veverimer Webcast Today at 4:30 pm Eastern Time Tricida, Inc. (NASDAQ:TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate,

  5. Tricida Announces FDA Acceptance of New Drug Application for Veverimer

    Tricida, Inc. (NASDAQ:TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic

  6. Tricida to Report Third Quarter Financial Results and Host Conference Call and Webcast on Thursday, November 14, 2019

    Tricida, Inc. (NASDAQ:TCDA) today announced that it will report its third quarter 2019 financial results after the close of market on Thursday, November 14, 2019. Tricida will host a conference call and webcast at 4:30

  7. Tricida to Host Investor Day on October 15, 2019

    Management to unveil veverimer (TRC101) U.S. commercialization strategy following recent NDA submission Leading clinicians and researchers to discuss implications of metabolic acidosis Live and archived webcast

  8. Tricida Announces Multiple Data Presentations on Metabolic Acidosis to be Given at ASN Kidney Week 2019

    Tricida, Inc. (NASDAQ:TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-dosed polymer designed to treat metabolic acidosis

  9. Tricida Launches Metabolic Acidosis Insights, an Online Educational Resource for the Healthcare Community

    Tricida, Inc. (NASDAQ:TCDA), a pharmaceutical company, announced today the launch of an educational website for healthcare providers. The website, https://metabolicacidosisinsights.com, is an online resource providing

  10. Tricida Announces Submission of New Drug Application for Veverimer for the Treatment of Metabolic Acidosis in Patients with Chronic Kidney Disease

    NDA Submitted under the FDA's Accelerated Approval Program Tricida, Inc. (NASDAQ:TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a